Esteve Pharmaceuticals, S.A.
Esteve Pharmaceuticals, S.A., commonly known as Esteve, is a prominent player in the global pharmaceutical industry, headquartered in Barcelona, Spain. Founded in 1929, Esteve has established itself as a leader in the development of innovative medicines, particularly in the fields of pain management, respiratory diseases, and central nervous system disorders. With a strong presence in Europe and Latin America, Esteve is recognised for its commitment to research and development, resulting in a diverse portfolio of unique products and services. The company’s dedication to quality and innovation has earned it a solid market position, marked by notable achievements in both therapeutic advancements and strategic partnerships. Esteve continues to focus on enhancing patient care through its specialised offerings, making it a trusted name in the pharmaceutical landscape.
DitchCarbon Score
How does Esteve Pharmaceuticals, S.A.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Esteve Pharmaceuticals, S.A.'s score of 39 is higher than 60% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Esteve Pharmaceuticals, S.A.'s reported carbon emissions
In 2024, Esteve Pharmaceuticals, S.A. reported total carbon emissions of approximately 274,764,000 kg CO2e. This figure includes 12,182,000 kg CO2e from Scope 1 emissions, 16,755,000 kg CO2e from Scope 2 emissions, and a significant 262,425,000 kg CO2e from Scope 3 emissions. Comparatively, in 2023, the company’s total emissions were about 290,708,000 kg CO2e, indicating a reduction of approximately 15,944,000 kg CO2e year-on-year. This reduction reflects the effectiveness of their ongoing emission reduction strategies. Notably, Esteve has achieved a cumulative reduction of 10.41% in total emissions compared to the base year of 2022, with a focus on Scope 3 emissions. Esteve Pharmaceuticals is committed to sustainability and actively implements strategies to mitigate its carbon footprint. The company has not reported any Science-Based Targets Initiative (SBTi) targets but continues to pursue its own reduction initiatives. The emissions data is not cascaded from any parent organization, indicating that Esteve independently manages its climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2009 | 2010 | 2011 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 9,982,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 16,014,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 11,963,000 | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Esteve Pharmaceuticals, S.A. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
